FinTechFunding

Kazia Therapeutics: Partners with DFCI to treat rare lymphoma

  • Cancer treatment specialist Kazia Therapeutics (KZA) is teaming up with the U.S. Dana-Farber Cancer Institute (DFCI) to treat a rare type of lymphoma
  • Kazia’s paxlisib drug will tested against primary central nervous system lymphoma (PCNSL), which is a specific type of cancer of the white blood cells
  • The trial will also recruit up to 25 patients who have relapsed or refractory PCNSL
  • Recruitment for the trial is slated for early 2021, and it’s expected to take two years to complete
  • The Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School
  • Shares in Kazia rose in early action but have since settled and are currently trading grey, worth 94 cents each
Previous article
Jatcorp: Develops new milk products, secures two-year distribution agreement
Next article
Optiscan Imaging: Plans $9.4M capital raise
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

JPMorgan Pilots Software to Monitor Junior Bankers’ Working Hours

New initiative aims to enhance oversight of junior employee hours worked.Highlights: JPMorgan tests software to monitor working hours...
FinTech

Goldman Sachs to Implement Performance-Based Staff Cuts in April

The bank plans restructuring amidst shifting financial landscape.Highlights: Goldman Sachs plans performance-based staff cuts in April.The restructuring aims...
FinTech

Nasdaq Secures SEC Approval for Trading Tokenized Securities

This marks a significant advancement in digital asset trading.Highlights: Nasdaq gains SEC approval for trading tokenized securities.This approval...
FinTech

Aveni Launches Agentic AI Council to Enhance AI Ethics

New council aims to guide ethical AI development and deployment strategies.Highlights: Aveni establishes the Agentic AI Council for...